The first new treatment for Alzheimer’s disease for nearly 20 years has been approved by regulators in the United States, paving the way for its use in the UK. Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms. Charities have welcomed the news of a new therapy for the condition. But scientists are divided over its potential impact because of uncertainty over the trial results.
